Αποτελέσματα Αναζήτησης
DESCRIPTION. ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE).
ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm 2 .It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE),and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.
ORTHO EVRA is an estrogen/progestin combination hormonal contraceptive (CHC), indicated for the prevention of pregnancy in women who elect to use a transdermal patch. (1) Limitation of Use:...
ACTIVE INGREDIENT(S): Norelgestromin (NGMN) and ethinyl estradiol (EE). o Summary of Product Characteristics (SmPC) before pre. embolism (VTE), and how the risk of VTE with EVRA. compares with other CHCs (see contraindications and special warn. Adults: Transdermal use. One patc. for 7 days, for 3 weeks followed by 1 week patch free. .
The following information is provided from studies of combination oral contraceptives. The use of the EVRA® (norelgestromin and ethinyl estradiol) transdermal system is expected to be associated with similar risks. The use of combination hormonal contraceptives (CHC) is associated with increased
SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
EVRA contains two types of sex hormones, a progestogen called norelgestromin and an oestrogen called ethinyl estradiol. Because it contains two hormones, EVRA is called a ‘combined hormonal contraceptive’.
